

TABLE OF CONTENTS

Neurologic Care and Pain Management I . . . 1

Neurologic Care and Pain Management I Panel	3
---	---

Attention-Deficit/Hyperactivity Disorder

By Kelly C. Lee, Pharm.D., MAS, FCCP, BCPP; and Jamie Kneebusch, Pharm.D., BCPS, BCPP

Introduction	7
Rating Scales	10
Guidelines	11
Nonpharmacologic Treatment	12
Pharmacologic Treatment	13
Goals of Therapy	21
Conclusion	23
References	24
Self-Assessment Questions	26

Epilepsy in Adults

By Sunita Dergalust, Pharm.D., BCPS; and Jacquelyn Louise Bainbridge, Pharm.D., BSPHarm, FCCP, MSCS, FAES

Introduction and Epidemiology	29
Classification, Etiology, Pathophysiology, and Clinical Presentation	30
Pharmacotherapy	35
Drug-Resistant Epilepsy	47
Special Populations and Comorbidity	48
Role of the Pharmacist in Epilepsy in the Ambulatory Care Setting	51
Conclusion	53
References	53
Self-Assessment Questions	56

Neurologic Care and Pain Management II . . . 61

Neurologic Care and Pain Management II Panel	63
--	----

Sleep-Wake Disorders

By Caitlin McCarthy, Pharm.D., BCPP; and Ian R. McGrane, Pharm.D., BCPS, BCPP

Introduction	67
Insomnia Disorder	67
Deprescribing for Insomnia Disorder	72
Narcolepsy	74
Obstructive Sleep Apnea	78
Circadian Rhythm Sleep-Wake Disorders	79
Restless Legs Syndrome	80
Conclusion	84
References	84
Self-Assessment Questions	87

Multiple Sclerosis

By Aimee M. Banks, Pharm.D., BCPS, MSCS

Introduction	91
Clinical Presentation and MS Subtypes	92
Treatment Goals in MS	95
MS in Special Populations	106
Conclusion	108
References	108
Self-Assessment Questions	112

Neurologic Care and Pain Management III 117

Neurologic Care and Pain Management III Panel	119
---	-----

Gabapentinoid Misuse

By Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTs; Jordan R. Covvey, Pharm.D., Ph.D., BCPS; and Levi S. Campbell, Pharm.D.

Basics of Gabapentinoids	123
Physiologic Basis for Effects	128
Emerging Evidence Regarding Misuse	128
Gabapentinoid Misuse Risk Mitigation	132
Recommendations for Pharmacists	133
Conclusion	135
References	136
Self-Assessment Questions	141

Opioid Overdose Prevention

By Jennifer Ball, Pharm.D., BCACP, BCGP; and Erin E. Miller, Pharm.D., MBA

Introduction	145
Pathophysiology of Opioid-Induced Harms	146
Naloxone for Opioid Overdose	148
Future Directions	150
Neurochemical Changes Associated with Opioid Use and Use Disorders	151
Identifying High Risk Patients	151
Approaches to Brief Intervention	153
Opportunities for Referral to Treatment	153
Practice Management	156
Harm Reduction	160
Advocacy and Community Development	160
Conclusion	161
References	161
Self-Assessment Questions	165

Neurologic Care and Pain Management IV...169

Neurologic Care and Pain Management IV Panel 171

Interactive Case: Statewide Tobacco Cessation Protocols

By Veronica P. Vernon, Pharm.D., BCPS, BCACP

Interactive Case: Statewide Tobacco Cessation Protocols ... 176

References 176

Self-Assessment Questions 180

Interactive Case: Migraine Headache

By Deanna S. Kania, Pharm.D., BCPS, BCACP

Interactive Case: Migraine Headache 184

References 184

Self-Assessment Questions 187

Interactive Case: Bias and Stigmatization in Substance Use Disorders

By Jennie B. Jarrett, Pharm.D., MMedEd, FCCP, BCPS; and Brianna M. McQuade, Pharm.D., MHPE, BCACP

Interactive Case: Bias and Stigmatization in Substance Use Disorders 191

References 192

Self-Assessment Questions 195